Concepedia

Timothy A. Yap

TA

Statistics

Publications

156

Citations

16K

H-Index

56

Active since

2006

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Institute of Cancer Research

Royal Marsden NHS Foundation Trust

Dana-Farber Cancer Institute

Royal Marsden Hospital

Timothy A. Yap is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and pharmacology.

ORCID

Publications per year

2006–2025

156

Publications

156

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

, , +17

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in <i>BRCA</i> Carrier Ovarian Cancer Correlating With Platinum-Free Interval

Peter C.C. Fong, Timothy A. Yap, David S. Boss et al. · Journal of Clinical Oncology · 2010 · 992 citations · Full text

, , +17

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Gerhardt Attard, Alison Reid, Timothy A. Yap et al. · Journal of Clinical Oncology · 2008 · 896 citations · Full text

, , +17

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

Jianfeng Shen, Wei Zhao, Zhenlin Ju et al. · Cancer Research · 2018 · 592 citations · Full text

, , +17

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Timothy A. Yap, Yan Li, Amita Patnaik et al. · Journal of Clinical Oncology · 2011 · 543 citations

, , +17

1–5 of 156